Endocyte, Inc. (NASDAQ:ECYT)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $20.85 and last traded at $19.98, with a volume of 65868 shares trading hands. The stock had previously closed at $19.86.
Several equities analysts have recently commented on ECYT shares. Zacks Investment Research upgraded Endocyte from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, July 10th. Wedbush raised their price target on Endocyte from $15.00 to $21.00 and gave the company an “outperform” rating in a research note on Monday, July 16th. BidaskClub upgraded Endocyte from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 21st. Finally, Jefferies Financial Group restated a “buy” rating and set a $21.00 price target on shares of Endocyte in a research note on Thursday, August 2nd. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $20.00.
The company has a market cap of $1.38 billion, a PE ratio of -19.01 and a beta of 0.23.
Endocyte (NASDAQ:ECYT) last posted its earnings results on Tuesday, July 31st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). Endocyte had a negative return on equity of 30.87% and a negative net margin of 69,330.66%. The company had revenue of $0.01 million for the quarter. equities research analysts forecast that Endocyte, Inc. will post -0.67 earnings per share for the current year.
In other Endocyte news, VP Christopher P. Leamon sold 13,089 shares of Endocyte stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $15.06, for a total value of $197,120.34. Following the transaction, the vice president now owns 130,381 shares in the company, valued at $1,963,537.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Beth Taylor sold 7,892 shares of Endocyte stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $20.00, for a total value of $157,840.00. Following the completion of the transaction, the vice president now owns 63,363 shares in the company, valued at approximately $1,267,260. The disclosure for this sale can be found here. Insiders sold 22,680 shares of company stock worth $382,743 in the last quarter. 14.86% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its holdings in Endocyte by 2,272.7% in the first quarter. Wells Fargo & Company MN now owns 33,218 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 31,818 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Endocyte in the first quarter worth about $141,000. Alambic Investment Management L.P. acquired a new stake in Endocyte in the first quarter worth about $136,000. Asymmetry Capital Management L.P. boosted its holdings in Endocyte by 12.2% in the first quarter. Asymmetry Capital Management L.P. now owns 91,435 shares of the biopharmaceutical company’s stock worth $831,000 after acquiring an additional 9,951 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Endocyte by 60.3% in the first quarter. Northern Trust Corp now owns 129,626 shares of the biopharmaceutical company’s stock worth $1,178,000 after acquiring an additional 48,770 shares in the last quarter. Institutional investors own 75.61% of the company’s stock.
About Endocyte (NASDAQ:ECYT)
Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.
Recommended Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.